Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TAK-003 in Children and Adolescents
NCT02302066Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2014
- Primary completion
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of dengue tetravalent vaccine (live, attenuated) in dengue fever, sponsored by Takeda. Started Dec 2014; status: completed.
02
Drugs
dengue tetravalent vaccine (live, attenuated)
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02302066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302066.